| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 188 | 208 | 190 | 189 | 192 | 237 | 213 | 215 | 251 | 267 | 259 | 223 | 275 | 286 | 270 | 243 | 289 | 327 | 308 | 277 | 350 | 360 | 333 | 309 | 395 | 461 | 420 | 398 | 461 | 504 | 488 | 562 | 717 | 744 | 726 |
| Expenses | 109 | 125 | 112 | 135 | 114 | 152 | 128 | 141 | 162 | 164 | 159 | 153 | 170 | 175 | 190 | 171 | 189 | 205 | 203 | 184 | 223 | 220 | 210 | 209 | 269 | 309 | 286 | 284 | 297 | 324 | 311 | 403 | 470 | 477 | 477 |
| EBITDA | 79 | 83 | 78 | 54 | 78 | 86 | 85 | 75 | 88 | 103 | 100 | 70 | 105 | 111 | 81 | 72 | 100 | 122 | 105 | 93 | 127 | 141 | 123 | 100 | 125 | 151 | 134 | 114 | 164 | 180 | 177 | 160 | 248 | 267 | 249 |
| Operating Profit % | 40 % | 37 % | 39 % | 27 % | 39 % | 34 % | 38 % | 32 % | 34 % | 37 % | 36 % | 28 % | 38 % | 38 % | 28 % | 30 % | 34 % | 37 % | 33 % | 33 % | 35 % | 38 % | 36 % | 31 % | 31 % | 32 % | 32 % | 28 % | 35 % | 35 % | 36 % | 26 % | 34 % | 35 % | 34 % |
| Depreciation | 5 | 5 | 6 | 7 | 5 | 5 | 7 | 9 | 7 | 8 | 10 | 11 | 12 | 12 | 13 | 14 | 10 | 11 | 11 | 12 | 15 | 15 | 17 | 18 | 23 | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 81 | 81 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 8 | 7 | 6 | 5 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 60 | 57 |
| Profit Before Tax | 73 | 78 | 72 | 48 | 74 | 99 | 77 | 62 | 78 | 92 | 89 | 58 | 95 | 103 | 72 | 62 | 95 | 116 | 99 | 85 | 117 | 131 | 109 | 85 | 101 | 121 | 107 | 76 | 113 | 126 | 116 | 77 | 115 | 129 | 116 |
| Tax | 11 | 8 | 4 | 1 | 3 | 6 | 3 | 6 | 6 | 7 | 9 | 4 | 11 | 10 | 9 | 5 | 6 | 8 | 9 | 17 | 10 | 12 | 8 | 5 | 8 | 2 | 6 | 14 | 19 | 4 | 14 | -3 | 26 | 33 | 29 |
| Net Profit | 63 | 69 | 68 | 47 | 71 | 93 | 75 | 56 | 72 | 86 | 80 | 54 | 84 | 93 | 64 | 56 | 89 | 108 | 90 | 68 | 107 | 118 | 101 | 80 | 93 | 119 | 100 | 62 | 94 | 122 | 102 | 80 | 89 | 96 | 87 |
| EPS in ₹ | 45.64 | 5.02 | 4.95 | 3.43 | 5.15 | 6.75 | 5.43 | 4.06 | 5.18 | 6.20 | 5.83 | 3.93 | 6.11 | 6.74 | 4.62 | 4.13 | 6.56 | 7.93 | 6.64 | 5.03 | 7.86 | 8.71 | 7.41 | 5.91 | 6.96 | 8.84 | 7.49 | 4.81 | 6.97 | 9.08 | 7.55 | 5.22 | 6.11 | 6.73 | 6.15 |
Eris Lifesciences
1,412.30
+6.85
(0.49%)
Market Cap
19,230.24 Cr
EPS
28.82
PE Ratio
58.20
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
1,593.90
52 Week Low
815.85
PB Ratio
6.92
Debt to Equity
0.76
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from8 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,723.00 | #1 4,13,405.42 | 35.22 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 54.16 | |
5,779.75 | 1,53,434.20 | 75.20 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 56.90 | |
1,452.90 | 1,17,338.37 | 24.00 | 26,520.70 | 14.17 | 4,155 | 47.38 | 51.80 | |
3,214.65 | 1,08,798.36 | 58.64 | 10,785.70 | 11.59 | 1,656 | 13.54 | 59.74 | |
2,423.20 | 99,976.03 | 49.78 | 10,615.60 | 19.57 | 1,942 | -16.38 | 59.91 | |
1,150.90 | 96,037.47 | #1 18.06 | 28,905.40 | 12.36 | 5,578 | 1.69 | 47.74 | |
2,000.00 | 91,308.19 | 32.14 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 47.45 | |
885.35 | 89,086.93 | 19.77 | 19,831.50 | 13.82 | 3,831 | 29.92 | 42.86 | |
1,156.75 | 67,184.23 | 19.21 | 29,559.20 | 17.55 | 3,169 | -10.04 | 53.81 | |
30,762.60 | 65,368.38 | 48.70 | 6,097.20 | 10.80 | 1,201 | 16.01 | 55.29 |
Growth Rate
Revenue Growth
19.85 %
Net Income Growth
6.12 %
Cash Flow Change
66.59 %
ROE
-26.88 %
ROCE
-14.45 %
EBITDA Margin (Avg.)
6.41 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,049 |
| Fixed Assets | 65 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,328 |
| Current Assets | 237 | 216 | 299 | 582 | 480 | 467 | 627 | 765 | 2,302 |
| Capital Work in Progress | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 |
| Investments | 144 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 |
| Other Assets | 190 | 192 | 324 | 435 | 595 | 685 | 807 | 1,041 | 2,686 |
| Total Liabilities | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,049 |
| Current Liabilities | 71 | 76 | 226 | 306 | 165 | 167 | 200 | 443 | 2,532 |
| Non Current Liabilities | 25 | 60 | 349 | 79 | 91 | 91 | 164 | 1,003 | 1,295 |
| Total Equity | 302 | 591 | 886 | 1,169 | 1,296 | 1,576 | 1,908 | 2,221 | 3,222 |
| Reserve & Surplus | 302 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,894 | 2,182 | 2,573 |
| Share Capital | 0 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 |
| Investing Activities | -92 | -44 | -185 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 |
| Operating Activities | 90 | 132 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 |
| Financing Activities | 1 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 |
Share Holding
| % Holding | Jan 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 55.55 % | 54.13 % | 52.69 % | 52.68 % | 52.66 % | 52.66 % | 52.30 % | 52.29 % | 52.70 % | 52.86 % | 52.86 % | 54.91 % | 54.90 % | 54.90 % | 54.88 % | 54.87 % | 54.86 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 13.20 % | 0.00 % | 14.27 % | 14.59 % | 8.01 % | 8.35 % |
| DIIs | 10.52 % | 9.25 % | 9.66 % | 9.57 % | 9.99 % | 10.11 % | 10.36 % | 10.38 % | 9.94 % | 10.02 % | 10.28 % | 14.53 % | 13.86 % | 15.63 % | 16.23 % | 18.64 % | 18.06 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 22.42 % | 23.28 % | 23.23 % | 23.29 % | 23.19 % | 23.14 % | 21.34 % | 21.27 % | 21.45 % | 21.66 % | 22.07 % | 15.47 % | 15.67 % | 14.24 % | 13.53 % | 10.51 % | 9.29 % |
| Others | 11.51 % | 13.34 % | 14.42 % | 14.46 % | 14.16 % | 14.09 % | 16.01 % | 16.07 % | 15.90 % | 15.46 % | 14.79 % | 1.90 % | 15.57 % | 0.95 % | 0.77 % | 7.96 % | 9.43 % |
| No of Share Holders | 29,195 | 41,470 | 46,477 | 49,833 | 54,223 | 57,061 | 51,639 | 48,055 | 46,746 | 45,931 | 44,169 | 42,245 | 46,496 | 51,753 | 44,176 | 46,346 | 53,314 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 2.87 | 5.5 | 6.01 | 7.35 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 0.8 | 1.05 | 0.87 | 0.00 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Closure of Trading Window
1 day ago
1 day agoClarification With Respect To Increase In Volume7 days ago
7 days agoClarification sought from Eris Lifesciences Ltd7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 07, 2025
Mar 07, 2025Announcement Under Regulation 30 - Sale Of SubsidiariesMar 06, 2025
Mar 06, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 06, 2025
Mar 06, 2025Announcement Under Regulation 30 - Update On Acquisition Of 30% Equity Stake In Levim Lifetech Private LimitedFeb 27, 2025
Feb 27, 2025Announcement Under Regulation 30 - Update On Acquisition Of 30% Equity Stake In Levim Lifetech Private LimitedFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Feb 24, 2025Announcement Under Regulation 30 - Redemption Of 43750 8% Secured Unlisted Redeemable Non-Convertible DebenturesFeb 21, 2025
Feb 21, 2025Announcement Under Regulation 30 - Availing Credit FacilitiesFeb 21, 2025
Feb 21, 2025Corporate GuaranteeFeb 19, 2025
Feb 19, 2025Corporate PresentationFeb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Feb 11, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Feb 11, 2025Corporate Action-Board approves DividendFeb 07, 2025
Feb 07, 2025Board Meeting Outcome for Declaration Of Interim DividendFeb 07, 2025
Feb 07, 2025Intimation Under Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revision In Record DateFeb 05, 2025
Feb 05, 2025Board To Consider Interim Dividend - Record DateFeb 04, 2025
Feb 04, 2025Closure of Trading WindowFeb 04, 2025
Feb 04, 2025Corporate Action-Board to consider DividendFeb 04, 2025
Feb 04, 2025Board Meeting Intimation for The Consideration Of The Declaration Of An Interim Dividend For The Financial Year 2024-25.Feb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 04, 2025
Feb 04, 2025Integrated Filing (Financial)Feb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 04, 2025
Feb 04, 2025Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 04, 2025
Feb 04, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On February 04 2025Feb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 29, 2025
Jan 29, 2025Board Meeting Intimation for Consideration And Approval Of Standalone And Consolidated Unaudited Financial Results For The Quarter & Nine Months Ended 31 December 2024.Jan 29, 2025
Jan 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 20, 2025
Jan 20, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 09, 2024
Dec 09, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 05, 2024
Dec 05, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 04, 2024
Dec 04, 2024General_UpdatesNov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 12, 2024
Nov 12, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 04, 2024
Nov 04, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 25, 2024
Oct 25, 2024Announcement under Regulation 30 (LODR)-AcquisitionOct 25, 2024
Oct 25, 2024Announcement under Regulation 30 (LODR)-Investor PresentationOct 25, 2024
Oct 25, 2024Financial Results For The Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Oct 25, 2024Board Meeting Outcome for Outcome Of The Board Meeting Held On October 25, 2024Oct 25, 2024
Oct 25, 2024Announcement under Regulation 30 (LODR)-AcquisitionOct 23, 2024
Oct 23, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 23, 2024
Oct 23, 2024Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024Oct 22, 2024
Oct 22, 2024Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 14, 2024
Oct 14, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 08, 2024
Oct 08, 2024Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 30, 2024
Sep 30, 2024Corporate GuaranteeSep 27, 2024
Sep 27, 2024Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 26, 2024
Sep 26, 2024Technical Indicators
RSI(14)
Neutral 63.75
ATR(14)
Volatile 71.46
STOCH(9,6)
Neutral 50.26
STOCH RSI(14)
Neutral 56.61
MACD(12,26)
Bullish 12.12
ADX(14)
Weak Trend 21.74
UO(9)
Bearish 53.13
ROC(12)
Uptrend And Accelerating 10.51
WillR(14)
Neutral -34.14
About Eris Lifesciences
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands and a distribution network of 22 sales depots, 2,059 stockists, and over 500,000 retail chemists. Eris has expanded through acquisitions and launches of new divisions. It has five wholly-owned subsidiaries and has acquired various brands and businesses in recent years, including dermatology and cosmetology brands. The company also produces human insulin and has entered the anti-thrombotics segment.
Listing Date
29 Jun, 2017(7 Years,
27 days)
Website
Chairperson NameAmit Indubhushan Bakshi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
